Related Experiment Video
Updated: Sep 21, 2026

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
Published on: June 14, 2021
Intravitreal tissue plasminogen activator for the treatment of central retinal vein occlusion
Jennifer S Weizer1, Sharon Fekrat
1Duke University Eye Center, Durham, North Carolina 27710, USA.
Abstract:
A 58-year-old hypertensive man with a perfused central retinal vein occlusion of 21 days' duration received 50 microg of intravitreal recombinant tissue plasminogen activator in 0.1 cc. Best-corrected visual acuity improved 2 weeks after the injection. Optical coherence tomography and fluorescein angiography demonstrated resolution of cystoid macular edema and improvement of venous outflow. Intravitreal tissue plasminogen activator may be a useful treatment for central retinal vein occlusion with a duration of 21 days or less.
More Related Videos
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Venous Thrombosis III: Interprofessional Care
Angle Closure Glaucoma: Treatment
